Fig. 3From: The ORVAC trial: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis: a statistical analysis planExpected sample size (total enrolled) assessed on clinical and immunological outcome over a range of baseline values, effect sizes and accrual ratesBack to article page